Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-Negative Breast Cancer × anlotinib × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 3 Thyroid Neoplasms 2 Sarcoma 2 Whole-Brain Radiotherapy 1 Sarcoma, Synovial 1 Sarcoma, Alveolar Soft Part 1 Proteinuria 1 Progression Free Survival(PFS) 1 Pancreatic Neoplasms 1 Lung Neoplasms 1 Leiomyosarcoma 1 HER2-Negative Breast Cancer 1 Carcinoma, Renal Cell 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07396454 2026-02-09

Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting

HER2-Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡